Directly observed therapy with sofosbuvir/ledipasvir for 8 weeks is highly effective in treatment-naïve, precirrhotic genotype 1 patients with borderline compliance receiving opioid agonist therapy

S. Moser,A. Schütz, K. Marchart, D. Kalchbrenner, G. Rechberger, J. Luhn, E. Gutic, H. Haltmayer,M. Gschwantler

JOURNAL OF HEPATOLOGY(2017)

引用 5|浏览6
暂无评分
摘要
An important subgroup of people who inject drugs (PWID) receives opioid agonist therapy (OAT) under direct observation of a physician or nurse at a low-threshold drug treatment facility or pharmacy on a daily basis. Most of these patients suffer from psychiatric comorbidities and are reluctant or unable to go to specialized hepatitis centers. Our hypothesis was that chronic hepatitis C in these difficult-to-treat patients could be optimally managed if modern, interferon-free regimens were applied together with OAT under direct observation of a physician or nurse at a low-threshold drug treatment facility.
更多
查看译文
关键词
opioid agonist therapy,sofosbuvir/ledipasvir,sofosbuvir/ledipasvir,precirrhotic genotype,borderline compliance
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要